634 completed. 634 Phase 2, 97 Phase 1, 52 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 634 | Completed 634 |
| Phase 1 | 97 | Completed 97 |
| Phase 3 | 52 | Completed 52 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Omega 3 Fatty Acids on Heart and Liver in Beta Thalassemia Patients Omega 3 Fish Oil supplements, Deferasirox - Thalassemia Majors (Beta-Thalassemia Major) | Phase 2 | Completed | Ain Shams University | 100 | 2026-01-01 | 2026-10-07 |
| A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD) HBI-002 - Anemia, Sickle Cell | Phase 2 | Completed | Hillhurst Biopharmaceuticals, Inc. | 13 | 2025-02-15 | 2026-08-06 |
| Zinc for Infection Prevention in Sickle Cell Anemia-2 (ZIPS-2) zinc sulfate, Placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Indiana University | 100 | 2025-02-10 | 2026-01-30 |
| A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH） HSK39297 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Completed | Haisco Pharmaceutical Group Co., Ltd. | 47 | 2024-07-17 | 2025-06-29 |
| Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease Etavopivat - Sickle Cell Disease | Phase 2 | Completed | Novo Nordisk A/S | 12 | 2024-03-09 | 2026-04-08 |
| Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Post Partum Iron Deficiency Anaemia Ferric Carboxymaltose (FCM) - Anemia, Anemia, Postpartum | Phase 2 / Phase 3 | Completed | ESI-PGIMSR, Basaidarapur | 200 | 2024-03-01 | 2026-06-15 |
| Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease Epeleuton - Sickle Cell Disease | Phase 2 | Completed | Afimmune | 35 | 2024-01-10 | 2026-05-04 |
| Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria HRS-5965 tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 26 | 2023-11-15 | 2024-10-15 |
| Assessing Physical Function in Sickle Cell Patients Taking Voxelotor Voxelotor - Sickle Cell Disease | Phase 2 | Completed | Inova Health Care Services | 6 | 2023-10-23 | 2026-08-31 |
| Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia L-glutamine - Pulmonary Artery Pressure, Thalassemia | Phase 2 / Phase 3 | Completed | Mazandaran University of Medical Sciences | 8 | 2023-08-15 | 2025-10-07 |
| Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias Tranexamic Acid (TXA) treatment, Placebo - Anemia, Small Bowel Bleeding | Phase 2 / Phase 3 | Completed | Louisiana State University Health Sciences Center in New Orleans | 40 | 2023-08-01 | 2025-08-15 |
| Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia Bitopertin - Steroid-refractory Diamond-Blackfan Anemia (DBA) | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2023-07-25 | 2026-06-30 |
| A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) MY008211A tablets - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 34 | 2023-07-06 | 2025-07-30 |
| An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Povetacicept - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 1 / Phase 2 | Completed | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 30 | 2023-07-03 | 2026-09-14 |
| Hydroxyurea and EPO in Sickle Cell Disease Hydroxyurea, Epoetin Alfa-BioSimilar - Anemia, Sickle Cell, Sickle Cell Disease | Phase 1 / Phase 2 | Completed | Julia Xu | 17 | 2023-05-25 | 2026-01-07 |
| Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Pazopanib, Placebo oral capsule - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Completed | Cure HHT | 71 | 2023-05-08 | 2026-10-27 |
| Assessing the Effect of a Mineral-enriched Powder on Iron Deficiency in Women of Reproductive Age Mineral-enriched powder, Placebo powder - Iron Deficiency, Iron Deficiency Anaemia | Phase 2 | Completed | Carleton University | 150 | 2023-04-27 | 2026-04-27 |
| Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab OMS906 - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | Omeros Corporation | 12 | 2023-03-27 | 2025-10-01 |
| Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury Iron dextran, Placebo - Anemia, Iron Deficiency, Acute Kidney Injury | Phase 2 | Completed | Hospital Civil de Guadalajara | 120 | 2023-01-06 | 2024-10-01 |
| Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia Luspatercept, Cyclosporine - Aplastic Anemia | Phase 2 | Completed | Bing Han | 58 | 2022-12-19 | 2025-09-16 |
Showing 20 of 634. Sign in to see all of them.
Anemia, Sickle Cell (140) · Myelodysplastic Syndromes (112) · Anemia, Refractory, with Excess of Blasts (103) · Leukemia (88) · Anemia, Aplastic (79) · Leukemia, Myeloid, Acute (73) · Leukemia, Myelomonocytic, Chronic (63) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (58) · Anemia, Refractory (51) · Myeloproliferative Disorders (45) · Leukemia, Lymphocytic, Chronic, B-Cell (42) · beta-Thalassemia (42) · Lymphoma, Non-Hodgkin (41) · Thalassemia (39)
Hemic and Lymphatic Diseases (634) · Hematologic Diseases (606) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (269) · Bone Marrow Diseases (263) · Anemia, Hemolytic (248) · Genetic Diseases, Inborn (219) · Pathological Conditions, Signs and Symptoms (212) · Anemia, Hemolytic, Congenital (195) · Pathologic Processes (194) · Hemoglobinopathies (178) · Disease Attributes (169) · Chronic Disease (151) · Neoplasms (144) · Neoplasms by Histologic Type (142)
Cyclophosphamide (69) · Cyclosporine (58) · fludarabine phosphate (54) · Antilymphocyte Serum (53) · Busulfan (49) · Mycophenolic Acid (39) · Epoetin Alfa (37) · fludarabine (37) · Whole-Body Irradiation (33) · Filgrastim (28) · Peripheral Blood Stem Cell Transplantation (28) · Tacrolimus (26) · Hydroxyurea (23) · Darbepoetin alfa (22) · Melphalan (22)
National Heart, Lung, and Blood Institute (NHLBI) (34) · Novartis Pharmaceuticals (29) · Fred Hutchinson Cancer Center (20) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (20) · Amgen (15) · Alexion Pharmaceuticals, Inc. (14) · GlaxoSmithKline (10) · Hoffmann-La Roche (10) · Memorial Sloan Kettering Cancer Center (10) · National Cancer Institute (NCI) (10) · Kyntra Bio (9) · Masonic Cancer Center, University of Minnesota (9) · Assistance Publique - Hôpitaux de Paris (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · UCSF Benioff Children's Hospital Oakland (8)
United States (387) · United Kingdom (65) · Italy (58) · France (51) · Germany (43) · Canada (42) · Spain (26) · South Korea (25) · Japan (24) · Lebanon (21) · China (19) · Turkey (Türkiye) (18) · Thailand (17) · Egypt (16) · Poland (15)
Danielle M Townsley, M.D. (5) · Neal S Young, M.D. (5) · Brenda Sandmaier (4) · Mary Horowitz, MD (4)
PMID 36005278, PMID 33783815, PMID 34724566, PMID 23738544, PMID 34175041, PMID 36240296, PMID 29958797, PMID 32499241, PMID 36791280, PMID 37975597, PMID 22067384, PMID 26494831, PMID 29669226, PMID 29674506, PMID 30957581, PMID 30992268, PMID 32343796, PMID 33283989, PMID 34922648, PMID 36355805, PMID 36529836, PMID 38775255, PMID 40569673, PMID 40593138, PMID 10029607, PMID 1090310, PMID 10924610, PMID 11581447, PMID 11910485, PMID 12622583, PMID 12957457, PMID 14770445, PMID 15352656, PMID 15520109, PMID 15667486, PMID 15817673, PMID 15860486, PMID 16114787, PMID 16158312, PMID 16381629, PMID 16411031, PMID 16834839, PMID 17233848, PMID 17263626, PMID 17330243, PMID 17519064, PMID 17531887, PMID 17541653, PMID 17699416, PMID 17910637
2016 (8), 2017 (7), P30CA015704 (7), 2014 (6), P01CA018029 (6), P30CA043703 (6), 2015 (5), P30CA006973 (4), U10CA031946 (4), U24CA076518 (4), 2005 (3), 2008 (3), 2018 (3), 2023 (3), P30CA016672 (3)